Biologic approvals, drug delivery advancements, GLP-1 generics and the long-sought funding return to drive a record year in 2025 13 …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

